MDxHealth S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael K. McGarrity
- Full Time Employees
- 252
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- CAP Business Center Herstal Belgium 4040
- IPO Date
- Apr 17, 2014
- Website
- mdxhealth.com
- Similar Companies
- Business
- MDxHealth SA, a commercial-stage precision diagnostics company founded in 2003 and headquartered in Herstal, Belgium, develops and markets molecular diagnostic tests to personalize the diagnosis, prognosis, and treatment of urologic cancers including prostate, bladder, and kidney cancers, as well as other urologic diseases. The company offers a portfolio of proprietary tissue-based and liquid biopsy-based tests utilizing genetic, epigenetic (methylation), exosomal, and other molecular technologies, including ConfirmMDx for post-biopsy prostate cancer detection to address sampling errors; SelectMDx, a urine-based pre-biopsy test to identify men at high or low risk for clinically significant prostate cancer; Genomic Prostate Score (GPS; formerly Oncotype DX Prostate), a tissue-based genomic assay for risk stratification in low- to high-risk localized prostate cancer to guide treatment decisions such as active surveillance; ExoDx Prostate (EPI), a non-invasive urine-based test assessing risk of high-grade prostate cancer with at-home collection option; AssureMDx for bladder cancer detection; ResolveMDx, combining sensitive assay with ASTX for urinary tract infection treatment selection; and InformMDx. MDxHealth operates CLIA-certified laboratories in Irvine, California; Waltham, Massachusetts; Plano, Texas; and Nijmegen, Netherlands, serving physicians, healthcare providers, hospitals, clinics, and laboratories primarily in the United States and Europe. In September 2025, the company closed its acquisition of the Exosome Diagnostics business from Bio-Techne Corporation for $15 million, incorporating the ExoDx Prostate test and related assets to expand liquid biopsy capabilities and accelerate revenue growth to approximately 30% in 2026; earlier acquisitions include the Oncotype DX GPS prostate test from Exact Sciences in 2022. MDxHealth reported preliminary Q2 2025 revenues of $26.6 million (up 20% year-over-year), positive adjusted EBITDA of $1.4 million, and reaffirmed 2025 revenue guidance of $108-110 million, with Q3 2025 revenues reaching $27.4 million (up 18%). The company appointed Michael Holder to its board of directors in July 2025 and continues strategic expansions in precision urology diagnostics.
MDxHealth Q1 Earnings Call Highlights
MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript
Head to Head Analysis: C.P. Pokphand (OTCMKTS:CPKPY) and MDxHealth (OTCMKTS:MXDHF)
MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript
Here's Why Momentum in MDxHealth SA (MDXH) Should Keep going
MDxHealth SA (MDXH) Reports Q2 Loss, Tops Revenue Estimates
MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript
MDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue Estimates
MDxHealth Reports Q1-2025 Results
Down -15.22% in 4 Weeks, Here's Why You Should You Buy the Dip in MDxHealth SA (MDXH)
MDxHealth SA (MDXH) Q4 2024 Earnings Call Transcript
MDxHealth SA (MDXH) Reports Q4 Loss, Tops Revenue Estimates
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance
MDxHealth: Strong Buy On Its Cutting-Edge Urology Diagnostics
MDxHealth to Participate in Piper Sandler Healthcare Conference
MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024
MDxHealth SA (MXDHF) Q3 2023 Earnings Call Transcript